One of the best-performing hedge funds this year and over the longer term is betting on health-care companies working to combat the coronavirus pandemic. The biotech-focused fund has returned 20% in 2020 on its long positions, when the market experience unprecedented disruption.
Here’s a look at its newest wagers in one of the hottest sectors amid the pandemic sell-off.